| Boehringer–Vanderbilt Univ: MCL1 inhibitors, 201803– collab expansion RnD of MCL1 inhibitors for cancer |
2018-03-13 |
| Danaher–KAUST: microscopy, 201803– collab establ KAUST-Leica Center of Excellence in Optical Microscopy |
2018-03-12 |
| ImmBioMed–Sekisui: coagulation tests, 201803 acquisiton of specialty coagulation assets of Sekisui Diagnostics GmbH by ImmBioMed |
2018-03-12 |
| KAUST–Danaher: microscopy, 201803 supply SP8 confocal platform to new KAUST-Leica Center of Excellence in Optical Microscopy |
2018-03-12 |
| Medical Univ Vienna–bio.logis: genetic software, 201803 collab use of bio.logis GIMS.DRM with safety code card at MUW |
2018-03-12 |
| Medigene–Informa: partnering conference, 201803 supply service Medigene participates in BIO-Europe Spring 2018 |
2018-03-12 |
| Medigene–Roth Capital Partners: investor conference, 201803 supply service Medigene presents at Annual Roth Conference 2018 |
2018-03-11 |
| Magenta Therapeutics–Heidelberg Pharma: antibody-drug conjugates, 201803– collab developm of ADCs for bone marrow transplant using ATAC platform |
2018-03-05 |
| abcr GmbH–Enzymicals: enzymes, 201803– collab distribution expansion ww catalogue sale of selected enzymes + enzyme-produced chemicals |
2018-03-01 |
| Heidelberg Pharma–MC Services: public relations, 201803 service existent by MC Services |
2018-03-01 |
| Heidelberg Pharma–Univ Texas: personalised medicine, 201803– license for Dx + Tx of cancer patients w RNA polymerase II deletion |
2018-03-01 |
| R-Biopharm–Bosch: molecular diagnostics, 201803– collab €na developm tests for Vivalytic platform + sale of system with tests by R-Biopharm |
2018-03-01 |
| Berlin Cures–Russo Partners: public relations, 201802 service existent by Russo Partners |
2018-02-26 |
| IRM² Infrarot Mikroskopie und Messtechnik GmbH–Bruker: investment, 201802 acquisition €na of IRM² by Bruker |
2018-02-22 |
| Cullinan Oncology–MAB Discovery: antibody cancer drug, 201802– collab developm of MAbs based on MAB Discovery’s discovery platform |
2018-02-20 |
| Mologen–SEVERAL: investment, 201802–201803 capital increase €4.99m with 2.36m new shares at €2.12/share to existing + new investors |
2018-02-15 |
| Affimed–SEVERAL: investment, 201802 public offering $26.5m ($24.5m net) with 12.5m+1.725m common shares at $2/share |
2018-02-12 |
| Pieris–Trophic Communications: public relations, 201802 service existent media relations by Trophic |
2018-02-09 |
| Thermo Fisher–Endress+Hauser: lab automation, 201802 collab product integration of AJ’s CyBio FeliX system in cell-free DNA extraction device |
2018-02-07 |
| 4SC–Life Sciences Partners: investor conference, 201802 supply service 4SC AG presents at BioCapital Europe 2018 |
2018-02-06 |
| Medigene–Life Sciences Partners: investor conference, 201802 supply service Medigene AG presents at BioCapital Europe 2018 |
2018-02-06 |
| Servier–ImmunoQure: therapeutic antibodies, 201802– collab developm of INF-alpha human autoantibody for autoimmune diseases |
2018-02-06 |
| Faron Pharmaceuticals–Lyomark Pharma: Traumakine, 201802– supply contract manfucturing by Lyocontract GmbH |
2018-02-05 |
| Faron Pharmaceuticals–Rentschler: Traumakine, 201802 supply existent contract manfucturing by Rentschler Biopharma SE |
2018-02-05 |
| TraitGenetics–SGS: investment, 201802 acquisition of TraitGenetics GmbH by SGS |
2018-02-02 |
| Cytosurge–Lab Automation Network: cell analysis technology, 201802– collab product integration to offer automated single-cell biology applications |
2018-02-01 |
| Silvacx–Merck (DE): nanoparticle technology, 201802– license excl to Silvacx delivery technology for cancer immunotherapy |
2018-02-01 |
| Silvacx–North Rhine-Westphalia (govt): grant, 201802– RnD grant €1.93m 3 years to develop Silvacx technology |
2018-02-01 |
| Biotest–Credit Suisse: financial services, 201704 supply service financial advisor with regard to sale of Biotest AG to Ceat Group (CN) |
2018-01-31 |
| Immunicum–Trophic Communications: public relations, 201801 service existent IR + media relations EU + US by Trophic |
2018-01-31 |
| eTherapists–Creathor Ventures: investment, 201801 financing round 7-digit € for Humanoo.com from Creathor + DvH Ventures et al |
2018-01-30 |
| eTherapists–SEVERAL: investment, 201801 financing round 7-digit € for Humanoo.com from Creathor + DvH Ventures et al |
2018-01-30 |
| Topas Therapeutics–Univ Hamburg: anti-inflammatory drugs, 201801– collab Topas excl translational partner for liver inflammation CRC at UKE |
2018-01-25 |
| High-Tech Gründerfonds–Dräger: investment, 201801 investment of Dräger in HTGF III Fund |
2018-01-23 |
| Novartis–Biocon: biosimilars, 201801– collab strategic ww excl developm + production + comercialisation Sandoz + Biocon |
2018-01-18 |
| Eximmium–Helmholtz: investment, 201801 seed funding €250k from Helmholtz Enterprise + Helmholtz Zentrum München at spin off of Eximmium |
2018-01-17 |
| Sartorius–Synpromics: genomic technology, 201801 collab existent with Sartorius Stedim Cellca |
2018-01-17 |
| Centogene–JPMorgan Chase: investor conference, 201801 supply service Centogene presents at JP Morgan Healthcare Conference 2018 |
2018-01-11 |
| BioNTech–Scancell: cancer immunotherapy, 201801– collab research using Moditope platform w excl license option for BioNTech |
2018-01-09 |
| CureVac–JPMorgan Chase: investor conference, 201801 supply service CureVac presents at JP Morgan Healthcare Conference 2018 |
2018-01-08 |
| Indivumed–EU (govt): credit, 201801– EIB/EFSI loan €40m to create Global Cancer Database Solution |
2018-01-08 |
| BioNTech–Fidelity: investment, 201801 financing round Series A totalling $270m incl new + co-investor Fidelity Management & Research |
2018-01-04 |
| BioNTech–Invus Group: investment, 201801 financing round Series A totalling $270m incl new + co-investor Invus |
2018-01-04 |
| BioNTech–Janus Henderson: investment, 201801 financing round Series A totalling $270m incl new + co-investor Janus Henderson Investors |
2018-01-04 |
| BioNTech–Redmile Group: investment, 201801 financing round Series A totalling $270m incl new + lead investor Redmile Group LLC |
2018-01-04 |
| BioNTech–SEVERAL: investment, 201801 financing round Series A $270m led by new investor Redmile Group LLC |
2018-01-04 |
| BioNTech–Strüngmann Group: investment, 201801 financing round Series A totalling $270m incl returning co-investor Strüngmann Family Office |
2018-01-04 |
| CureVac–Arcturus Therapeutics: mRNA therapeutics, 201801– strategic collab for lipid-mediated mRNA drugs using RNAoptimizer + LUNAR system |
2018-01-04 |
| CureVac–BMC Communications: public relations, 201801 service existent by BMC |
2018-01-04 |
| Rewind Therapeutics–Boehringer: investment, 201801 financing round Series A totalling €15.2m incl co-lead investor BIVF |
2018-01-04 |
| Themis Bioscience–Trophic Communications: public relations, 201801 service existent by Trophic |
2018-01-04 |
| BASF–Biocrates: investment, 201801 acquisition of Metanomics Health GmbH by Biocrates from BASF Plant Science GmbH |
2018-01-03 |
| Biocrates–BASF: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund |
2018-01-03 |
| Biocrates–MIG Fonds: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund |
2018-01-03 |
| Biocrates–Xolaris Service KVG: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund |
2018-01-03 |
| Centogene–MacDougall Biomedical Communications: public relations, 201801 service existent by MacDougall |
2018-01-03 |
| Central BioHub–in.vent Diagnostica: in vitro diagnostics, 201801 collab existent |
2018-01-02 |
| Clariant–Global Bioenergies: biopolymers, –201801 collab developm bio-based polymers for cosmetics developed w sugar-based isobutene |
2018-01-02 |
| Aquila Biolabs–Germany (govt): investment, 2018 financing round pre-Series A totalling 7-digit € incl investor KfW Bankengruppe |
2018-01-01 |
| Aquila Biolabs–PERSON: investment, 2018 financing round pre-Series A totalling 7-digit € incl investor Jürgen Schumacher |
2018-01-01 |
| Aquila Biolabs–PERSON: investment, 2018 financing round pre-Series A totalling 7-digit € incl investor Robert Huber |
2018-01-01 |
| Aquila Biolabs–Seed Fonds Aachen: investment, 2018 financing round pre-Series A totalling 7-digit € incl investor Seed Fonds Aachen II |
2018-01-01 |
| Aquila Biolabs–SEVERAL: investment, 2018 financing round pre-Series A 7-digit € from Seed Fonds Aachen II + KfW + J Schumacher + R Huber |
2018-01-01 |
| Dopavision–Germany (govt): grant, 2018– BMBF grant €1.4m over 3 years |
2018-01-01 |
| Pfizer–BioNTech: mRNA-based vaccines, 2018– collab development of influenza vaccines |
2018-01-01 |
| Siemens–OTHER: investment, 2018H1 PLANNED listing of newSiemens Healthineers AG at Frankfurt Stock Exchange |
2018-01-01 |
| BioNTech–ICR: public relations, 201712 service existent by ICR Healthcare in US |
2017-12-21 |
| BioNTech–JPMorgan Chase: investor conference, 201801 supply service BioNTech presents at JP Morgan Healthcare Conference 2018 |
2017-12-21 |
| Boehringer–Autifony: CNS drugs, 201712–202008 collab €25m upfront + €627.5m milestones excl option to KV3.1/3.2 modulators for BI TERMINATED 8/20 |
2017-12-18 |
| Fast Track Diagnostics–Siemens: investment, 201712 acquisiton €na of FTD by Siemens Healthineers |
2017-12-15 |
| Evotec–TU Dresden: drug discovery, 201712– collab research €na small-molecule candidates for retinal diseases using iPSC technology with CRTD |
2017-12-13 |
| Flexion Therapeutics–GeneQuine: gene therapy, 201712 acquisition $2m upfront + $62.7m milestones + royalties ww rights to GQ-203 by Flexion |
2017-12-13 |
| Oncgnostics–SEVERAL: investment, 201712–201801 crowdfunding campaign €750k via Seedmatch platform |
2017-12-12 |
| AbeXXa Biologics–Boehringer: investment, 201712 existent investment by BIVF |
2017-12-11 |
| Aelin Therapeutics–Boehringer: investment, 201712 financing round Series A totalling €27m incl investor BIVF |
2017-12-11 |
| Boehringer–AbeXXa Biologics: drug target research, 201712 collab existent to identify molecular protein targets for cancer |
2017-12-11 |
| Boehringer–Univ California: cancer vaccine, 201712 collab existent to develop vaccine technology platform with UCLA |
2017-12-11 |
| Hookipa–Boehringer: investment, 201712 financing round Series C totalling €50m incl returning investor BIVF |
2017-12-11 |
| thinXXS Microtechnology–Idex Corporation: investment, 201712 acquisition of thinXXS Microtechnology AG by Idex Corp |
2017-12-11 |
| PGS.Holland–bio.logis: genetic software, 201712– distribution of bio.logis GIMS in Benelux + Scandinavia + UK by PGS.Holland BV |
2017-12-08 |
| Hepa Wash–Germany (govt): business development, 201712– supply service support in US with German Accelerator Life Sciences programme |
2017-12-07 |
| Evotec–Berenberg: investor conference, 201712 supply service Evotec presents at Berenberg European Conference in Surrey |
2017-12-06 |
| Novartis–Medigene: Veregen, 201712– acquisition €na of US rights to Veregen by Fougera Pharmaceuticals Inc |
2017-12-05 |
| Probiodrug–Crossbeta Biosciences: biomarker research, 201712– collab extension developm Alzheimer biomarker to support Probiodrug’s clinical program |
2017-12-05 |
| Probiodrug–MC Services: public relations, 201712 service existent by MC Services |
2017-12-05 |
| Probiodrug–Optimum Strategic Communications: public relations, 201712 service existent by Optimum |
2017-12-05 |
| Probiodrug–Trout Group: public relations, 201712 service existent by The Trout Group |
2017-12-05 |
| Evotec–Ncardia: drug discovery technology, 201712– license ww non-excl €na to access iPSC-derived disease models of Ncardia |
2017-12-04 |
| Institut Virion\Sirion–ExpreS2ion Biotech: expression technology, 201712– collab using ExpreS2 platform for antigen production for IVD tests |
2017-12-04 |
| I-Mab–MorphoSys: antibody cancer drug, 201711– license excl Greater China for MOR202 with $20m upfront + $100m milestones + tiered 2-digit royalties |
2017-11-30 |
| Abivax–Deutsche Börse: investor conference, 201711 supply service Abivax presents at Deutsches Eigenkapitalforum 2017 |
2017-11-28 |
| Bitkom–Bayer: digital economy, 201711 Bayer is member of Bitkom w particular focus on digital health + digital farming |
2017-11-27 |
| Boehringer–BioMed X: pharma research, 201711– collab new BioMed X research group in bacterial modulation of innate immunity |
2017-11-27 |
| Evotec–Deutsche Börse: investor conference, 201711 supply service Evotec AG presents at Deutsches Eigenkapitalforum 2017 |
2017-11-27 |
| Evotec–Volks- und Raiffensenbanken (DE): investor conference, 201711 supply service Evotec attends DZ Bank Equity Conference 2017 in Ffm |
2017-11-22 |
| SimLeap project–Bicoll: sweetener, 201711–2019 collab Bicoll is project partner |
2017-11-17 |
| SimLeap project–Charité: sweetener, 201711–2019 collab Charité is project partner |
2017-11-17 |
| SimLeap project–Germany (govt): grant, 201711–2019 BMB funding €1.1m out of total project volume of €1.6m |
2017-11-17 |
| SimLeap project–Symrise: sweetener, 201711–2019 collab Symrise is project partner |
2017-11-17 |
| High-Tech Gründerfonds–EWE: investment, 201711 € 7-figure investment in HTGF III fund by EWE AG |
2017-11-16 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
